NR1H4 and metabolic dysfunction-associated steatohepatitis: In another phase II clinical trial, Cenicriviroc was combined with the farnesoid X receptor (FXR) agonist Tropifexor to improve the hepatic fibrosis in patients with MASH, but the result analysis is still ongoing (172).